Successful ruxolitinib administration for a patient with steroid‐refractory idiopathic pneumonia syndrome following hematopoietic stem cell transplantation: A case report and literature review
Dan Tomomasa, Takeshi Isoda, Noriko Mitsuiki, Motoi Yamashita, Aoi Morishita, Takahiro Tomoda, Tsubasa Okano, Akifumi Endo, Takahiro Kamiya, Masakatsu Yanagimachi, Kohsuke Imai, Hirokazu Kanegane, Masatoshi Takagi, Tomohiro Morio
Abstract
Idiopathic pneumonia syndrome (IPS) is an acute lung complication observed after the early posthematopoietic stem cell transplantation (HSCT) period. Ruxolitinib was effective for a patient with myelodysplastic syndrome who developed severe IPS after second HSCT. No severe adverse effects were observed. Ruxolitinib may be an alternative choice for HSCT-related IPS.
Topics & Concepts
MedicineRuxolitinibHematopoietic stem cell transplantationPneumoniaAdverse effectStem cellCryptogenic Organizing PneumoniaTransplantationComplicationRefractory (planetary science)LungInternal medicineIntensive care medicineBone marrowGeneticsBiologyPhysicsAstrobiologyMyelofibrosisMyeloproliferative Neoplasms: Diagnosis and TreatmentInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisEosinophilic Disorders and Syndromes